The company continue to develop this program for the WHO markets, thereby providing coverage and protection for more infants globally in time to come
Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore
Aurobindo Pharma Foundation endeavours to make a positive contribution to the underprivileged ommunities by supporting a wide range of socio-economic, educational, and health initiatives.
Active pharmaceutical ingredients revenue for the quarter was at Rs 913 crore
Subscribe To Our Newsletter & Stay Updated
